Side-by-side · Research reference

GDF-8vsLivagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/48 cited

BAnimal-StrongHUMAN-REVIEWED20/32 cited

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

Livagen

Khavinson Bioregulator · Hepatoprotective Tetrapeptide

50%Dipeptidase inhibitionTimofeeva 2005

Oral / SQRoutes tested

LiverTarget tissueKhavinson 2001

Oral or SQ · Tissue-specific to liver

01Mechanism of Action

Parameter

GDF-8

Livagen

Primary target

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Hepatocyte protein synthesis machineryBrodskiĭ 2001

Pathway

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001 Khavinson 2001

Downstream effect

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes

Feedback intact?

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

—

Origin

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)

Antibody development

—

02Dosage Protocols

Parameter

GDF-8

Livagen

Clinical use

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

—

Inhibition strategies

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

—

VLP immunogen (MS2.87-97)

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

—

Dual immunization (MSTN + Activin A)

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

—

Gene editing outcomes

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

—

Animal dose (oral)

—

Not specified in abstracts; 2-week administration protocolTimofeeva 2005

Per os administration in rats.

Duration (experimental)

—

2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005 Brodskiĭ 2001

Route

—

Oral or subcutaneous

Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005

Evidence basis

—

Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005 Brodskiĭ 2001 Khavinson 2002

Human data

—

None in provided literature

03Metabolic / Fat Loss Evidence

Parameter

GDF-8

Livagen

Primary mechanism

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

—

Human genetic evidence

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

—

Animal model outcomes

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

—

Adipose-muscle crosstalk

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

—

Metabolic benefits

Improved metabolic health in genetic MSTN null modelsJacquez 2026

—

Age-related effects

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

—

04Side Effects & Safety

Parameter

GDF-8

Livagen

Genetic null phenotype

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

—

Antibody cross-reactivity risk

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

—

VLP immunotherapy safety

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

—

Echocardiography

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

—

Pleiotropic effects (gene editing)

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

—

Assay variability

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

—

Reported adverse effects

—

None documented in animal studies

Human safety data

—

No human trials in provided literature

Peptide hydrolysis

—

Weakly hydrolyzed; minimal breakdown by intestinal enzymesTimofeeva 2005

Absolute Contraindications

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

Livagen

—

Relative Contraindications

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

Livagen

—

05Administration Protocol

Parameter

GDF-8

Livagen

1. Research context only

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005 Khavinson 2001

2. Inhibition strategies

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005

3. VLP immunization protocol (animal model)

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005

4. Gene editing considerations

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

—